The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3244-3249

  Skinner Adams, Tina S ^a   Peatey, Christopher L ^a   Anderson, Karen ^a   Trenholme, Katharine R ^a,b   Krige, David ^c   Brown, Christopher L ^d   Stack, Colin ^e   Nsangou, Desire M M ^f   Mathews, Rency T ^f   Thivierge, Karine ^f   Dalton, John P ^f   Gardiner, Donald L ^a,d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Chroma Therapeutics Ltd   (United Kingdom)

^d GRIFFITH UNIVERSITY   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

[2 (HYDROXYCARBAMOYLMETHOXYMETHYL) 4 METHYLPENTANOYLAMINO]PHENYLACETIC ACID; AMINO ACID; AMINOPEPTIDASE; ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; BESTATIN; CHR 2863; CHR 6769; HEMOGLOBIN; M1 ALANINE AMINOPEPTIDASE; M17 LEUCINE AMINOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIGESTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; MALARIA; MOUSE; NONHUMAN; PARASITE DEVELOPMENT; PARASITEMIA; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TREATMENT RESPONSE;

AMINOPEPTIDASES; ANIMALS; ANTIMALARIALS; ENZYME INHIBITORS; FEMALE; MALARIA; MICE; MICE, INBRED C57BL; PLASMODIUM FALCIPARUM;

EID: 84861161965     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06245-11     Document Type: Article

References (36)

1. Dalal S, Klemba M. 2007. Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum. J. Biol. Chem. 282:35978-35987. (Pubitemid 350277126)
2. Dev V, Phookan S, Sharma VP, Dash AP, Anand SP. 2006. Malaria parasite burden and treatment seeking behavior in ethnic communities of Assam, Northeastern India. J. Infect. 52:131-139. (Pubitemid 43137396)
3. Enserink M. 2008. Epidemiology. Lower malaria numbers reflect better estimates and a glimmer of hope. Science 321:1620.
4. Ersmark K, et al. 2004. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J. Med. Chem. 47:110-122. (Pubitemid 38040495)
5. Friesner RA, et al. 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47:1739-1749. (Pubitemid 38380917)
6. Gardiner DL, Trenholme KR, Skinner-Adams TS, Stack CM, Dalton JP. 2006. Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin. J. Biol. Chem. 281:1741-1745.
7. Gavigan CS, Machado SG, Dalton JP, Bell A. 2001. Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling. Antimicrob. Agents Chemother. 45:3175-3181. (Pubitemid 32988846)
8. Greenwood JR, Calkins D, Sullivan AP, Shelley JC. 2010. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J. Comput. Aided Mol. Des. 24:591-604.
9. Grembecka J, Mucha A, Cierpicki T, Kafarski P. 2003. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. J. Med. Chem. 46:2641-2655. (Pubitemid 36702533)
10. Halgren TA, et al. 2004. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47:1750-1759. (Pubitemid 38380918)
11. Harbut MB, et al. 2011. Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases. Proc. Natl. Acad. Sci. U. S. A. 108:E526-E534.
12. Ichinose Y, et al. 2003. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J. Natl. Cancer Inst. 95:605-610. (Pubitemid 36553507)
13. Krige D, et al. 2008. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 68:6669-6679.
14. Lew VL, Macdonald L, Ginsburg H, Krugliak M, Tiffert T. 2004. Excess haemoglobin digestion by malaria parasites: a strategy to prevent premature host cell lysis. Blood Cells Mol. Dis. 32:353-359. (Pubitemid 38581853)
15. Li X, et al. 2009. Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria. Biochem. Biophys. Res. Commun. 380:454-459.
16. Li X, Chen H, Jeong JJ, Chishti AH. 2007. BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria. Mol. Biochem. Parasitol. 155:26-32. (Pubitemid 47042214)
17. Lowenberg B, et al. 2010. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 28:4333-4338.
18. Luksch T, et al. 2008. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors. ChemMedChem 3:1323-1336.
19. Marks F, et al. 2005. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J. Infect. Dis. 192:1962-1965. (Pubitemid 41681894)
20. McGowan S, et al. 2010. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases. Proc. Natl. Acad. Sci. U. S. A. 107:2449-2454.
21. McGowan S, et al. 2009. Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proc. Natl. Acad. Sci. U. S. A. 106:2537-2542.
22. Mugittu K, et al. 2004. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.Am.J. Trop. Med. Hyg. 71:696-702. (Pubitemid 40075616)
23. Noedl H, et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
24. Nosten F, et al. 2004. Malaria in pregnancy and the endemicity spectrum: what can we learn? Trends Parasitol. 20:425-432. (Pubitemid 39485677)
25. Nwaka S, Hudson A. 2006. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5:941-955. (Pubitemid 44660607)
26. Park MS, Gao C, Stern HA. 2011. Estimating binding affinities by docking/scoring methods using variable protonation states. Proteins 79:304-314.
27. Peters WRB. 1999. Handbook of animal models of infection. Academic Press, London, United Kingdom.
28. Rogers WO, et al. 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J. 8:10.
29. Rosenthal PJ. 2002. Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Curr. Opin. Hematol. 9:140-145. (Pubitemid 34171491)
30. Schlitzer M. 2007. Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem 2:944-986.
31. Shelley JC, et al. 2007. Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21:681-691.
32. Skinner-Adams TS, et al. 2007. Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds. J. Med. Chem. 50:6024-6031.
33. Skinner-Adams TS, et al. 2010. Plasmodium falciparum neutral aminopeptidases: new targets for antimalarials. Trends Biochem. Sci. 35:53-61.
34. Stack CM, et al. 2007. Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J. Biol. Chem. 282:2069-2080. (Pubitemid 47076702)
35. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
36. Uhlemann AC, Krishna S. 2005. Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr. Top. Microbiol. Immunol. 295:39-53. (Pubitemid 41236510)